Antiviral drug poses threat to premature infants

Article

Premature babies who receive lopinavir/retonavir (Kaletra) oral solution immediately after birth to treat HIV-1 infection are at risk of serious heart, kidney, or breathing problems, the United States Food and Drug Administration (FDA) warns.

Premature babies who receive lopinavir/retonavir (Kaletra) oral solution immediately after birth to treat HIV-1 infection are at risk of serious heart, kidney, or breathing problems, the United States Food and Drug Administration (FDA) warns.

The oral solution contains propylene glycol, which premature infants have difficulty eliminating, and alcohol. Buildup of propylene glycol can lead to serious or even fatal adverse effects on the heart, kidney, and lungs.

FDA is revising the labeling of lopinavir/retonavir to warn against giving it to premature infants until 14 days after their due date or to full-term infants younger than 14 days of age because a safe and effective dose for these infants has not been established. In those cases when a healthcare professional believes that the benefit to the infant outweighs the potential risks, FDA strongly recommends monitoring the infant for increases in serum osmolality, serum creatinine, and other signs of toxicity.

Recent Videos
Efficacy found from biopsychosocial approach to women’s sexual health | Image Credit: hermd.com.
Dr. Somi Javaid highlights disparities in sexual health | Image Credit: hermd.com.
How advancements in IVF are impacting embryologist workload and patient care | Image Credit: fertility.coopersurgical.com/our_experts
Study finds no causal link between maternal health in pregnancy and autism risk | Image Credit: med.nyu.edu/faculty.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How early genetic testing empowers parents and improves outcomes | Image Credit: tuftsmedicine.org
Dallas Reed highlights trends and barriers in prenatal genetic testing | Image Credit: tuftsmedicine.org
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
How the cobas liat assay panels improve STI detection | Image Credit: labqualityconfab.
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Related Content
© 2025 MJH Life Sciences

All rights reserved.